Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human tests begin for experimental drug TEV-56286

NCT ID NCT07674940

Recruiting now Knowledge-focused Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Aug 07, 2026 · Updated 6 times

Summary

This early-stage trial tests the safety and how the body handles TEV-56286 (also known as emrusolmin or anle138b) in healthy adults. Participants receive either single or multiple rising doses of the drug or a placebo. The study measures how the drug is absorbed, distributed, and eliminated, and monitors for any side effects. Results will help determine safe doses for future studies in people with diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TEV-56286 (emrusolmin, anle138b)
What this could lead to
If safe and well-tolerated, this could pave the way for future studies testing TEV-56286 as a treatment for diseases like Parkinson's or other protein-aggregation disorders.
What could go wrong
This is an early, first-in-human trial in healthy volunteers, so it cannot show whether the drug works for any disease. Side effects or poor tolerability may stop further development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Teva Investigational Site 12174

    RECRUITING

    Miramar, Florida, 33025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.